Research location
Barcelona
Catalonia, Spain
Research activity in Barcelona
Catalonia, SpainCureCurrent currently publishes aggregate city-level research activity for this location: 374 trials and 516 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Barcelona
374 linked trials · page 2 of 8Dominantly Inherited Alzheimer Network (DIAN)NCT00869817 · 2009-01-01 · 1 site observation
RECRUITING
PENSA+: Extended Follow-up of a Multimodal Lifestyle Intervention to Prevent Cognitive Decline in APOE-ε4 CarriersNCT07730671 · 2026-09-01 · 1 site observation
NOT_YET_RECRUITING
REACTION-VAD Trial: Remote Exercise Training Via Telemedicine in Patients With Long-Term Ventricular Assist DevicesNCT07611188 · 2026-05-01 · 2 site observations
NOT_YET_RECRUITING
Netrod-Pilot Study of Renal Denervation With NetrodTM Sixelectrode Radiofrequency RDN SystemNCT07061054 · 2026-04-01 · 1 site observation
NOT_YET_RECRUITING
Efficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and InsomniaNCT07555743 · 2026-04-01 · 1 site observation
NOT_YET_RECRUITING
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesNCT07284901 · 2026-01-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluating a Personalised Online Program With Human Support for Women With Depression and Its Impact on Mental Health and Biological ChangesNCT07060690 · 2026-01-01 · 1 site observation
NOT_YET_RECRUITING
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686 · 2025-12-19 · 2 site observations
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesNCT07284875 · 2025-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765 · 2025-11-25 · 2 site observations
ACTIVE_NOT_RECRUITING
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128 · 2025-08-18 · 3 site observations
ACTIVE_NOT_RECRUITING
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)NCT06966479 · 2025-05-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)NCT06898957 · 2025-05-16 · 2 site observations
ACTIVE_NOT_RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)NCT06925750 · 2025-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCNCT06745323 · 2025-02-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Qualitative Study on Advanced Breast Cancer Patients and Their Caregivers in SpainNCT06683482 · 2025-02-21 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)NCT06721156 · 2024-12-16 · 1 site observation
TERMINATED
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984 · 2024-12-09 · 3 site observations
ACTIVE_NOT_RECRUITING
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)NCT06664801 · 2024-11-14 · 1 site observation
COMPLETED
The Personalized Psychological Treatment for PsychosisNCT06603922 · 2024-10-01 · 1 site observation
UNKNOWN
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).NCT06333951 · 2024-09-17 · 2 site observations
ACTIVE_NOT_RECRUITING
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441 · 2024-07-16 · 2 site observations
ACTIVE_NOT_RECRUITING
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabNCT06211036 · 2024-06-05 · 3 site observations
ACTIVE_NOT_RECRUITING
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsNCT06131398 · 2024-03-07 · 2 site observations
COMPLETED
ANTES B+ Clinical TrialNCT06282861 · 2024-02-29 · 1 site observation
TERMINATED
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)NCT06117774 · 2024-02-20 · 4 site observations
ACTIVE_NOT_RECRUITING
The Clinical Impact of the Novel Alzheimer's Blood-based BiomarkersNCT06246019 · 2024-02-07 · 1 site observation
UNKNOWN
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)NCT06074588 · 2023-11-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart FailureNCT05598333 · 2023-10-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) for DepressionNCT06590025 · 2023-09-13 · 1 site observation
UNKNOWN
Observational Study to Validate a Family Physician Echocardiography Training ProgrammeNCT07339007 · 2023-09-12 · 1 site observation
ENROLLING_BY_INVITATION
The Effects on Physical Activity on Mitochondrial Function in Skin Fibroblasts in Patients with Parkinson's Disease.NCT05963425 · 2023-09-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid TumorsNCT05975073 · 2023-08-01 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 · 2023-08-01 · 1 site observation
COMPLETED
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT05785767 · 2023-06-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Risk Stratification Using MEESSI-AHF Scale in ED and Impact on AHF OutcomesNCT05919225 · 2023-06-27 · 1 site observation
UNKNOWN
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung CancerNCT05740566 · 2023-05-31 · 3 site observations
ACTIVE_NOT_RECRUITING
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPDNCT05612035 · 2023-03-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)NCT05454410 · 2023-03-13 · 1 site observation
COMPLETED
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast CancerNCT05583110 · 2023-03-08 · 1 site observation
TERMINATED
Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)NCT05602727 · 2022-12-02 · 2 site observations
TERMINATED
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.NCT05562934 · 2022-11-08 · 1 site observation
COMPLETED
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersNCT05544929 · 2022-10-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)NCT05508867 · 2022-10-18 · 1 site observation
COMPLETED
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionNCT05325866 · 2022-09-23 · 2 site observations
TERMINATED
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)NCT05361395 · 2022-08-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 InsertionNCT05419700 · 2022-08-05 · 2 site observations
COMPLETED
Study of Efficacy and Safety of LTP001 in Pulmonary Arterial HypertensionNCT05135000 · 2022-06-30 · 1 site observation
TERMINATED
Impact of a Multimodal Prehabilitation Program Before Robotic-assisted Radical Prostatectomy.NCT05553327 · 2022-05-31 · 1 site observation
COMPLETED
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)NCT05298423 · 2022-05-03 · 2 site observations
COMPLETED
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.